Summary Tamoxifen as sole initial therapy is gaining importance in the management of post-menopausal breast cancer patients. Age, oestrogen (ER) and progesterone (PR) receptor status are accurately considered to select patients for hormonal treatment. However, additional markers are needed. By immunohistochemistry (IHC), we studied tumour expression of ER, PR, pS2, c-erbB-2 and glutathione S-transferase 7r (GSTh) on initial core biopsies of 208 post-menopausal patients with a non-metastatic invasive ductal carcinoma, treated by neoadjuvant tamoxifen therapy. A good response to tamoxifen was defined as tumoral regression >50% (110 patients). Relationship between response and age, tumour size, T, N, histological grade, ER and PR contents evaluated by radioimmunoassay, ER, PR, pS2, c-erbB-2 and GSTx expression evaluated by IHC were studied. Univariate and multivariate analysis showed that tumoral regression was linked only to pS2 (P = 0.004) and ER (P=0.018) IHC expression. According to the immunohistochemical profile, three groups could be defined: pS2-and ER-positive tumours, pS2-or ER-positive tumours and pS2-and ER-negative tumours with response rates of 60%, 45% and 8% respectively. Although prospective studies are needed to confirm these results, we conclude that pS2 and ER immunohistochemical status are useful tools for predicting tumour regression with neoadjuvant tamoxifen in post-menopausal breast carcinoma patients.
The incidence of breast neoplasm increases with age. Onethird of cases affect women older than 65 years. However, management of breast carcinomas in the elderly remains controversial. While some authors defend surgical treatment (Robertson et al., 1992a) , others have demonstrated the advantage of tamoxifen as sole initial therapy (Gazet et al., 1988; Akhtar et al., 1991; Horobin et al., 1991; Foudraine et al., 1992; Bergman et al., 1995) . In two randomised studies (Gazet et al., 1988; Robertson et al., 1992a) , no difference in survival was found between the surgical and tamoxifen groups. Robertson et al observed only a better locoregional control in the mastectomy group, although not statistically significant. In fact, in elderly and frail patients, shorter life expectancy, concomitant diseases and increased surgery risk are prominent factors determining treatment choice. However, there is no precise way of knowing which patients can be treated with tamoxifen only as primary treatment. Until now, age and hormonal receptor status have been the main factors for identifying patients with hormone-sensitive tumours. Yet, in post-menopausal cohorts of breast cancer patients, in spite of a high proportion of ER-positive tumours, 30% to 60% of patients fail to respond to primary tamoxifen therapy (Gaskell et al., 1989; Akhtar et al., 1991; Horobin et al., 1991; Robertson et al., 1992a; Foudraine et al., 1992; Bergman et al., 1995) . So it seems essential to look for additional markers of hormone responsiveness.
New insights into immunohistochemical techniques and new antibodies available make retrospective studies possible. In addition to ER and PR, new proteins more or less linked to hormonal receptors (HRs) have recently been isolated. Their role as prognostic factors and hormone-responsiveness markers has been suggested. Among them, we decided to examine pS2 protein, glutathione S-transferase ir (GSTx) and c-erbB-2 oncogene. pS2 protein was first identified in the human breast cancer cell line MCF-7 in response to oestrogen stimulation (Masiakowski et al., 1982) . Recently, it has been proposed as a candidate for prediction of hormone-related tumour regression (Henry et al., 1989; Schwartz et al., 1991; Hurlimann et al., 1993; Wilson et al., 1994) . Similarly, c-erbB-2 proto-oncogene, whose prognostic value in breast carcinomas is still controversial, has recently been implicated in predicting hormone-related tumour regression (Wright et al., 1992; Nicholson et al., 1993) . GSTm enzyme is thought to play a role in the intracellular detoxification of a wide range of xenobiotics and anti-neoplastic drugs. In a preliminary study using dot-blot mRNA hybridisation, we found a link between response to tamoxifen therapy and low levels of GSTir mRNA (DorionBonnet et al., 1993 Bouin -Holland-fixed paraffin-embedded sections were cut and mounted with 3'-amino-propyltriethoxysilane coating. Relationship between clinical response and IHC parameters ER IHC>10%, PR IHC >10%, pS2 > 3%, GSTr> 0 and cerbB-2 > 0 were crossed with group A (responders) and group B (non-responders). Results are shown in Table II . A significant relationship was found between ER IHC positivity and a good response (P= 0.016). Additionally, we observed a strong relationship between pS2 positivity and a good response with a P-value = 0.006. Response to hormonal therapy was correlated neither with PR IHC nor with GSTx or c-erbB-2.
Analysis of discrepancies between ER (DCC) and ER IHC results Analysis of discrepancies revealed ten cases in the ER IHCpositive/ER (DCC)-negative group. Six (60%) responded to tamoxifen, three (30%) showed partial regression and one 
Discussion
Tamoxifen has been advocated as first-line therapy in postmenopausal patients with locoregional disease for several reasons. It has a low toxicity with few side-effects. It can offer tumour regression before surgery and may represent an alternative to surgery or radiotherapy in frail patients, thus allowing good initial remission rates (Akhtar et al., 1991; Foudraine et al., 1992) . Unlike Bergman et al. (1995) , who showed a low response rate of 37.6%, we observed a good 5 month remission rate of 53% (with the same regression rate of at least 50%). This rate rose to 77% with inclusion of minor responses (25-50%). This should certainly be attributed to the high percentage of ER-positive tumours in our series (84.6% by DCC and 82.5% by IHC). In fact, this is higher than expected in a group of post-menopausal women. Most of the patients who entered neoadjuvant tamoxifen therapy had an HR-positive tumour, either both ER and PR or one of those. Only 18 tumours (9%) by DCC and 15 tumours (7%) by IHC were both ER and PR negative. Although delayed response can be obtained with tamoxifen therapy (Bergman et al., 1995) , we chose to evaluate tumour response after 5 months of treatment for several reasons. First of all, most responses appear to occur during the first 5 months (Gaskell et al., 1989; Akhtar et al., 1991; Robertson et al., 1992a; Bergman et al., 1995) . Moreover, some patients could benefit from a secondary treatment that we did not wish to delay. This latter point remains controversial (Bradbeer et al., 1983; Gazet et al., 1988; Akhtar et al., 1991; Robertson et al., 1992a; Bergman et al., 1995) al., 1981; Katz et al., 1990; Frigo et al., 1995) . Furthermore, HR status determined either on core biopsies or on fine-needle aspirates maintains its predictive value on prognosis and on tumour responsiveness to hormonal treatment (Coombes et al., 1987; Mauriac et al., 1989; Gaskell et al., 1989 Gaskell et al., , 1992 Davies et al., 1991) . Immunohistochemistry has both several advantages and limitations with regards to the DCC method, a theme widely discussed elsewhere (Pertschuk et al., 1985; McClelland et al., 1986; Hurlimann et al., 1993; de Mascarel et al., 1995) . As previously reported by some authors (McCarty et al., 1985; Pertschuk et al., 1985 Pertschuk et al., , 1990 McClelland et al., 1986; Robertson et al., 1992b; Hurlimann et al., 1993) (Henry et al., 1989 (Henry et al., , 1991 Schwartz et al., 1991; Hurlimann et al., 1993; Wilson et al., 1994) except one (Luqmani et al., 1993) , we confirm in our series the relevance of pS2 to predict tamoxifen-related tumour regression, especially when combined with ER r12 1124 status. We also note that pS2 alone was as predictive as ER alone and that pS2 expression was not linked to ER status. This strengthened its value in the logistic regression analysis. Only one of 13 patients with both pS2-and ER-negative status responded to tamoxifen while 60% (77/127) with both positive markers did, as well as 45-48% of those with either one. These results may appear lower than expected, but it has to be stressed that we chose to consider only responses superior to 50% of tumour regression. In this series, consideration of both markers improved predicition of tamoxifen-related tumour regression We did not find any link between c-erbB-2 expression and response to primary tamoxifen therapy. The two previous studies (Wright et al., 1992; Nicholson et al., 1993) were done in series different from ours, concerning either recurrences or an admixture of locally advanced primary tumours and relapses. Both studies showed a significant but weak relationship between c-erbB-2 positivity and reduced response rate. It is difficult to know whether these divergent results are related to the differences between our series and the others, or if c-erbB-2 is definitely not a powerful candidate for predicting hormone responsiveness.
PR status is classically supposed to reflect the functionality of the oestrogen receptor. Combined with the latter, it is considered to improve prediction of response to endocrine therapy (Ravdin et al., 1992; Klijn et al., 1993) . Surprisingly, In this series, it did not help to identify hormone-responsive tumours. This unexpected finding was previously reported by other authors (Schwartz et al., 1991; Hurlimann et al., 1993) .
In cases of adjuvant or palliative therapy, a discordance in steroid receptor content between primary and metastatic lesions could certainly be ascribed since progressive disease is thought to correlate with tumour dedifferentiation or development of poorly differentiated clones. However, this does not concern our series since steroid receptor assessment and tamoxifen-related tumour regression were done on primary tumours. So although tamoxifen is thought to act mainly through oestrogen receptors, mechanisms of tumour responsiveness or resistance seem to be much more complex. To investigate tamoxifen's molecular effects, we studied immunohistochemical changes of ER, PR, pS2, GST7r and c-erbB-2 under tamoxifen therapy in the group of 74 patients operated on after 5 months of tamoxifen. These results are reported in another paper (Soubeyran et al., 1996) .
Finally, these promising results warrant further consideration of pS2 as being an important candidate for predicting tamoxifen-induced regression of breast carcinomas in both post-menopausal patients and perhaps in younger patients. Prospective studies are required to confirm these data and improve them by testing new markers.
